Ciena ( CIEN) estimates reduced at UBS through 2010. Company has little revenue visibility, and likely can't cut costs fast enough. Neutral rating and $6.25 price target. Ciena ( CIEN) upgraded at Credit Suisse to Neutral from Underperform. Stock essentially hit its target price of $6. Rockwell Collins ( COL) upgraded at Goldman Sachs to Neutral from Sell. Company lowered its 2009 guidance in the midst of poor environment for business jets. Believe negatives are priced into shares. Price target trimmed to $26 from $28. Frontline ( FRO) rated new Underperform at Credit Suisse based on projected sharp earnings decline due to lower VLCC rates. Sets $10 target price. Genzyme ( GENZ) downgraded at Goldman Sachs to Sell from Buy based on increasing momentum in health care legislation, delays in Myozyme manufacturing and currency headwinds. Healthcare reforms could cut prices on expensive biotech drugs, and note that shares could be volatile later in 2009 due to Phase 2 data from Shire and Amicus. Price target cut to $61 from $85. Macy's ( M) upgraded at Bank of America/Merrill Lynch to neutral from underperform and $8 price target maintained. After recent stock drop, analyst believes that consensus and management's expectation are realistic and current valuation is appropriate. Macy's ( M) upgraded at Goldman Sachs to Buy from Neutral based on decreased balance sheet risk, market share gains, and improved earnings power after cost cutting. Note that biggest catalyst for shares would be increasing sale store sales. Price target raised to $8.25 from $8.